亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

医学 中性粒细胞减少症 不利影响 内科学 皮疹 白细胞减少症 贫血 中止 胃肠病学 肺炎 布鲁顿酪氨酸激酶 毒性 酪氨酸激酶 受体
作者
Yuqin Song,Wei Xu,Yongping Song,Lihong Liu,Song Lin,Zhiming Li,Ting Liu,Shuhua Yi,Daobin Zhou,Mingzhi Zhang,Yu Hu,Jie Jin,Huaqiang Zhu,Zhengguang Lu,Ren-Bin Zhao,Zhixin Xu,Jun Zhu
出处
期刊:Blood [American Society of Hematology]
卷期号:136 (Supplement 1): 43-43 被引量:7
标识
DOI:10.1182/blood-2020-140172
摘要

Background: Bruton tyrosine kinase (BTK) is one of the key kinases implicated in the pathogenesis of multiple B cell malignancies. Orelabrutinib is a novel, highly selective and potent irreversible BTK inhibitor with minimal activities against other kinases (ITK, EGFR, ERBB2, etc.). As thus orelabrutinib may avoid off-target related adverse events and shall have improved safety profiles comparing to other BTK inhibitors. Here we present the safety profile of orelabrutinib analyzed based on data from 5 ongoing clinical studies in B cell malignancies (Table 1). Methods: Safety data of 266 patients (pts) from 5 ongoing orelabrutinib monotherapy studies were pooled and analyzed. All pts have been treated with at least one dose of oral orelabrutinib at ≥150 mg daily. The analysis includes the frequency and severity of adverse events (AEs), AEs of special interest, and AEs leading to treatment discontinuation or dose modifications. Results: Safety data were pooled from 266 pts with median age of 60 years (range 35.0-79.0, 69.2% males). The median duration of exposure was 11.0 months (range 0.2-22.0). The most common (occurring in ≥15% of pts) AEs were neutropenia (28.6%), thrombocytopenia (25.9%), Upper respiratory tract infection (24.4%), leukopenia (18.0%), anemia (16.2%) and rash (15.8%). Treatment related serious AEs (SAEs) were reported in 14.7% pts. The most common treatment related SAEs included thrombocytopenia (3.0%), lung infection (3.0%), pneumonitis (1.9%), anemia (1.1%) and lymphadentis (0.8%), The safety profiles were comparable in pts with various subtypes of B cell malignancies. It's noted that orelabrutinib has much less frequency of BTK off-target related adverse events, such as atrial fibrillation, diarrhea, major hemorrhage etc. Among all 266 pts, only one patient was reported with one episode of transient grade 1 atrial fibrillation, and no grade ≥3 atrial fibrillation was observed. Diarrhea of any grade was 7.1% and only one case (0.4%) was reported as grade 3. The major hemorrhage, defined as serious or ≥ G3 bleeding of any site, or central nervous system bleeding of any grade, was rarely observed; as only one case of cerebral hemorrhage, in 65-year-old male patient with more than 10 years hypertension was reported; the other three cases were subcutaneous hemorrhage, vitreous hemorrhage and vitreous hemorrhage/retinal hemorrhage. The later 2 cases of vitreous hemorrhage and/or retinal hemorrhage were resulted from posterior vitreous detachment and macular degeneration and both events were assessed as unlikely related to the treatment. Among 266 pts, the second primary malignancies were reported in only one pt with r/r MCL during orelabrutinib treatment. Grade ≥3 infection occurred in 41 pts (15.4%); most common infections were upper respiratory tract infection and lung infection. Most of the AEs were occurred during the early treatment, the frequency of the new event occurrence was significantly decreased during the later cycles. Dose reductions due to AEs occurred in 15 pts (5.6%), and treatment discontinuation due to AEs in 5.3% of pts with 2.3% related to orelabrutinib. Conclusions: Orelabrutinib shows excellent safety profiles and tolerability across various B-cell malignancies in long-term treatment. These data suggested orelabrutinib as a favorable treatment choice including the combinational therapy for B-cell malignancies. . Disclosures Zhu: Beijing InnoCare Pharma Tech Co., Ltd: Current Employment. Zhao:Beijing InnoCare Pharma Tech Co., Ltd: Current Employment. Xu:Beijing InnoCare Pharma Tech Co., Ltd: Current Employment.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健的小迷弟应助小圆圈采纳,获得10
刚刚
5秒前
冬瓜排骨养生汤完成签到,获得积分10
23秒前
1分钟前
小圆圈发布了新的文献求助10
1分钟前
vantie完成签到 ,获得积分10
1分钟前
1分钟前
zhanglongfei完成签到,获得积分10
1分钟前
Luis发布了新的文献求助10
1分钟前
4分钟前
4分钟前
北陆玄枵发布了新的文献求助10
4分钟前
4分钟前
4分钟前
4分钟前
5分钟前
Dan完成签到,获得积分10
5分钟前
5分钟前
lcs完成签到,获得积分10
5分钟前
5分钟前
Owen应助lucky采纳,获得10
5分钟前
lucky完成签到,获得积分20
6分钟前
6分钟前
lucky发布了新的文献求助10
6分钟前
HHW完成签到,获得积分10
6分钟前
慕青应助tangyuan采纳,获得10
7分钟前
7分钟前
7分钟前
tangyuan发布了新的文献求助10
7分钟前
kokocrl完成签到,获得积分10
8分钟前
棉花糖猫弦完成签到 ,获得积分0
8分钟前
科研通AI2S应助tangyuan采纳,获得30
9分钟前
9分钟前
9分钟前
大个应助十三采纳,获得10
9分钟前
10分钟前
nevillmissy完成签到 ,获得积分20
10分钟前
10分钟前
10分钟前
10分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3150609
求助须知:如何正确求助?哪些是违规求助? 2802008
关于积分的说明 7846050
捐赠科研通 2459372
什么是DOI,文献DOI怎么找? 1309219
科研通“疑难数据库(出版商)”最低求助积分说明 628696
版权声明 601757